Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Stock Report

| More

Zydus' Desidustat shows efficacy and safety in treating Hypoxia in hospitalized Covid-19 patients in Mexico

Posted On: 2021-01-24 20:38:51 (Time Zone: Arizona, USA)

Zydus, a leading discovery based global pharmaceutical company today announced that it has received positive results from Phase 2(b) studies of Desidustat in COVID-19 patients [ClinicalTrials. govIdentifier: NCT04463602] conducted at Mexico.

Patients infected with COVID-19 have been reported to display signs of 'Hypoxia' leading to organ failure and death despite the use of antivirals, anti-inflammatory drugs or ventilators. The attack with the novel coronavirus pneumonia (COVID-19) will cause less and less haemoglobin that can carry oxygen and carbon dioxide. The lung cells have been reported to develop extremely intense poisoning and inflammation, shortness of breath sets in and this can lead to acute respiratory distress syndrome (ARDS). Patients with ARDS may require mechanical ventilator support to help circulate oxygen in the body.

Speaking on the development, Pankaj R. Patel, Chairman, Zydus Group said, "We are excited to report for the first time, this encouraging data of our novel HIF-PH inhibitor, Desidustat, showing the potential to help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients. ARDS is associated with high mortality rate and Zydus remains committed to further develop this novel therapy for patients suffering from ARDS."

The Phase 2(b) results of this study revealed that Desidustat treatment led to increased red blood cell production and improved oxygen delivery to tissues. None of the hospitalised patients required mechanical ventilator in the Desidustat arm, while 25% of COVID-19 patients on the standard of care arm required mechanical ventilation. Further the level of CRP and IL-6 are reported to predict respiratory failure in hospitalized symptomatic COVID-19 patients.

It has been reported that the risk of respiratory failure for patients with IL-6 levels of > 80 pg/ml was 22 times higher compared to patients with lower IL-6 levels (Refer: Tobias et al, Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19, Journal of Allergy and Clinical Immunology, VOLUME 146, ISSUE 1, P128-136.E4, JULY 01, 2020 doi: 10.1016/j.jaci.2020.05.008.). In this Phase 2(b) clinical study, the standard of care reported the mean increase in IL-6, while the Desidustat arm remained stabilised. Detailed reports will be published in a scientific journal.

Zydus had conducted the Phase 2b, Multicenter, Open-label, Randomized, ComparatorControlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of COVID-19 patients. Clinical and regulatory development of Desidustat in COVID-19 was executed in Mexico by Avant Santé Research Center S.A. de C.V., a leading Contract Research Organization (CRO) headquartered in Monterrey, Mexico. [ClinicalTrials.gov_ Identifier: NCT04463602]

Zydus had initiated two Phase III trials of Desidustat. The DREAM-ND Phase III trial is being conducted in 588 CKD patients not-on-dialysis [ Identifier: NCT04215120]. The DREAM-D Phase III trial is being conducted in 392 CKD patients on Dialysis [ClinicalTrials.gov_ Identifier: NCT04012957]. Desidustat is also being studied in Cancer Chemotherapy Induced Anemia [ Identifier: NCT04667533]. Desidustat had previously met its primary endpoints in the Phase II clinical studies and showed good safety profile. The Phase I trials were earlier completed in Australia.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.460.3 as compared to the previous close of Rs. 469.4. The total number of shares traded during the day was 138476 in over 2850 trades.

The stock hit an intraday high of Rs. 473.15 and intraday low of 455.35. The net turnover during the day was Rs. 64399911.

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

Glenmark signs on Rohit Sharma as brand ambassador of Candid Powder

Waa Solar Ltd Board aprovies 1:1 Bonus Issue

Coal India Ltd board approves 2nd interim dividend of Rs. 5

WeP Solutions Limited fixes March 12, 2021 as record date for rights issue

HGS Digital Partners with Automation Anywhere to Deliver End-to-End Process Automation Solutions in the Customer Experience Industry

PNB Housing Finance and YES BANK enter into strategic co-lending partnership

PVR Cinemas unveil Mysuru's Biggest 6-Screen multiplex in Forum Centre City Mall

Shilpa Medicare Ltd receives US FDA tentative approval for Apremilast Tablets, 10 Mg, 20 Mg, And 30 Mg

RITES Ltd Board to consider Second Interim Dividend on Mar 12, 2021

Mexico's GigNet selects Tejas Networks for its Metro Optical network in Cancun

Dilip Buildcon Ltd receives LOA from NHAI for 2 projects under Bangalore Chennai Expressway

BCPL Railway Infra secures path-breaking order in the railway electrification segment

Indian Bank to consider raising funds of Rs. 4000 crore through equity

Economic Times awards The Byke Hospitality Ltd. for Affordable Luxury Resort Stay

IndiGo strengthens regional connectivity, announces Bareilly as its 67th destination

TATA Tea Gold celebrates this Women's day by launching 'Dil Ki Suno' stories of today's women

Dabur launches 'Vatika Select' premium range of shampoos

Isgec to Set Up World's Largest Waste Heat Recovery Boilers

CRISIL updates on ratings of Brookfield India Real Estate Trust

Max Healthcare Institute Limited opens QIP, fixes floor price as Rs. 190.40

Engineers India Ltd board to consider interim dividend for FY21

Wipro to acquire Capco, a global management and technology consultancy to banking and financial services industry, for $ 1.45 billion

AI Champdany Industries Ltd announces temporary suspension of work at Unit - Wellington Jute Mill - Rishra

Honeywell Automation India limited names Dr. Ganesh Natarajan as Chairman

Laurus Labs Ltd's promoters have sold shares to release pledge on shares

Jay Shree Tea & Industries Ltd to sell Tea Estates at Valparai

TCS a Leader in Digital Finance and Accounting Business Process Services: IDC MarketScape

Unichem Laboratories Ltd receives ANDA approval for Guanfacine Tablets

NBCC India Limited executes MoU with Rashtriya Ispat Nigam Ltd

Dilip Buildcon Ltd receives LOA from Mahanadi Coalfield Ltd for mining project in Odisha

Torrent Power Ltd updates on power distribution tender

Ind-Ra upgrades long-term issuer rating of Prism Johnson Ltd

Hind Rectifiers Limited secures order of Rs. 72.02 crores

Reliance Power Limited and JERA JV achieves financial closure for power project in Bangladesh

Smruthi Organics Ltd fixes March 12, 2021 as record date for bonus issue

Thomas Cook India & SOTC partner with Air Asia & Sterling Holiday Resorts to leverage travel demand

Vivimed's FDF facility in Jeedimetla Obtained Ukraine GMP Approval (renewal)

Sangam Renewables Limited arm commissions 16MW solar project

ABB India joins hands with Lila Poonawalla Foundation to build future women leaders in technology

Wardwizard Innovations & Mobility Limited fixes record date for stock split

Ashoka Buildcon enters into SPA with IIF for acquiring 49% stake in SPV

TCS to Help VodafoneZiggo Accelerate its B2B Fixed Fiber Network Rollout Using AI

RailTel Corporation of India Ltd receives order from BSNL

Finolex Cables strengthens its FMEG portfolio!

IEX electricity market sees splendid 50% YoY volume growth in February 2021

ACUITE A- long-term rating assigned to Superhouse Limited

Shilpa Medicare Limited enters into Gynecology Segment by launching its First Women Intimate Cleansing Spray in India under the Brand Name 'SwatchShil'

Satin Creditcare Network Ltd re-certified as Great Place to Work™ second year in a row

Aleor Dermaceuticals receives USFDA Final Approval for Testosterone Gel, 1.62% (20.25 mg/1.25 gm actuation)

eBay in India joins hands with 75 years old Kerala Ayurveda, aims at introducing authentic Ayurveda for the US market

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020